Scientific Sessions 2025  /  HFpEF and CKM Syndrome: Overlap, Interplay and Opportunities to Optimize Outcomes  /  From clinical trials to practice: refining the care model for HFpEF
Logo

American Heart Association

  36
  0

Final ID:

From clinical trials to practice: refining the care model for HFpEF

  • Vaduganathan, Muthiah  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Butler, Javed  ( Baylor Scott and White Research , Dallas , Texas , United States )
    • Author Disclosures:
    Muthiah Vaduganathan: DO have relevant financial relationships ; Consultant:American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi, Cytokinetics, Esperion, Fresenius Medical Care, Idorsia Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Milestone Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi and Tricog Health:Active (exists now) ; Research Funding (PI or named investigator):Amgen, AstraZeneca, Boehringer Ingelheim, Galmed, Novartis, Bayer AG, Occlutech, Pharmacosmos, and Impulse Dynamics:Active (exists now) | Javed Butler: DO have relevant financial relationships ; Consultant:Abbott :Active (exists now) ; Consultant:Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, Zoll:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:CVRx:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Cardior:Active (exists now) ; Consultant:Cardiac Dimension:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:AskBio:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:American Regent:Active (exists now) ; Consultant:Adaptyx:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

HFpEF and CKM Syndrome: Overlap, Interplay and Opportunities to Optimize Outcomes

Saturday, 11/08/2025 , 03:15PM - 04:30PM

Cardiovascular Seminar

More abstracts on this topic:
Addressing the ubiquity of excess adiposity in HFPEF

Vest Amanda, Borlaug Barry, Butler Javed

CKD in HFpEF: A forgotten therapeutic target

Van Spall Harriette, Lambers Heerspink Hiddo

More abstracts from these authors:
COPD and Cardiopulmonary Risk: A Critical Connection

Vaduganathan Muthiah

GDMT and Hyperkalemia: A Crossroad for Cardiology Finding an Optimal Path

Vaduganathan Muthiah

You have to be authorized to contact abstract author. Please, Login
Not Available